Home » FDA Strengthens Hepatitis B Warning on Two Cancer Drugs
FDA Strengthens Hepatitis B Warning on Two Cancer Drugs
The FDA has upped its warnings on two cancer drugs: GlaxoSmithKline’s Arzerra and Roche and Biogen Idec’s Rituxan. The agency says that the two may cause the hepatitis B virus to reactivate in carriers.
Reuters
Reuters
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May